

AR 226 - 1477

TAFT, STETTINIUS & HOLLISTER LLP

NORTHERN KENTUCKY OFFICE
SUITE 340
1717 DIXIE HIGHWAY
COVINGTON, KENTUCKY 41011-4704
606-331-2838
513-381-2838
FAX: 513-381-6613

DAYTON, OHIO OFFICE
SUITE 900
110 NORTH MAIN STREET
DAYTON, OHIO 45402-1786
937-228-2838
FAX: 937-228-2816

425 WALNUT STREET, SUITE 1800
CINCINNATI, OHIO 45202-3957

513-381-2838
FAX: 513-381-0205

www.taftlaw.com

CLEVELAND, OHIO OFFICE
3500 BP TOWER
200 PUBLIC SQUARE
CLEVELAND, OHIO 44114-2302
216-241-2838
FAX: 216-241-3707

COLUMBUS, OHIO OFFICE
21 EAST STATE STREET
COLUMBUS, OHIO 43215-4221
614-221-2838
FAX: 614-221-2007

ROBERT A. BILOTT
(513) 357-9638
bilott@taftlaw.com

8EHQ-80-373
8EHQ-0803-00373
August 7, 2003

TELECOPY AND FEDERAL EXPRESS

Richard H. Hefter, Chief
High Production Volume Chemicals Branch
U.S. Environmental Protection Agency
Office of Pollution Prevention and Toxics
1200 Pennsylvania Avenue, N.W.
Washington, D.C. 20460-0001

Document Processing Center (7407M)
EPA East - Room 6428 Attn: Section 8(e)
U.S. Environmental Protection Agency
Office of Pollution Prevention and Toxics
1200 Pennsylvania Avenue, N.W.
Washington, D.C. 20460-0001

Re: TSCA Section 8(e) Reporting For PFOA



000811865T

Dear Mr. Hefter:

As a further supplement to our July 3, July 31, and August 5, 2003, letters on the referenced topic, we have enclosed a copy of a C-8 blood model developed by E.I. duPont de Nemours and Company ("DuPont"), which relates to DuPont's knowledge of estimated levels of perfluorooctanoate concentrations in the blood of the communities exposed to DuPont's C-8 emissions in air and water, as of October 10, 2001.

Very truly yours,

Robert A. Bilott

RAB:mdm

Enclosure

cc: Dr. Charles M. Auer (USEPA OPPT) (w/o encl.)
Mary Dominiak (USEPA OPPT) (for inclusion in AR-226) (w/ encl.)
Jennifer Seed (USEPA) (w/ encl.)
R. Edison Hill, Esq. (w/ encl.)
Larry A. Winter, Esq. (w/ encl.)
Gerald J. Rapien, Esq. (w/o encl.)

2003 AUG 14 AM 10:52
RECEIVED
OPPT NCIC
Contain No CBI